| Application: | Remove Fat |
|---|---|
| Disposable: | Disposable |
| Gender: | Unisex |
| Side Effect: | No |
| Usage: | For External Use |
| Pharmaceutical Technology: | Chemical Synthesis |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
Based on the natural human GLP-1 molecule, the eighth (alanine → alpha-aminobutyric acid) and the 34th amino acid (lysine → arginine) were substituted, while lysine at the 26th was linked to the C18 adipose acid side chain by spacer group. After the modification of human GLP-1 molecule, Smeiglutide can resist the degradation of dipeptidyl peptidase 4 (DPP-4), bind closely to albumin, significantly prolong the half-life in vivo, achieve once a week administration, and retain up to 94% of GLP-1 amino acid sequence homology, with good safety.
In December 2017, the US Food and Drug Administration (FDA) approved Smegalutide injection for the control of blood sugar in adults with type 2 diabetes.
In January 2020, it was approved by the FDA to reduce the risk of major cardiovascular adverse events in adults with type 2 diabetes with cardiovascular disease.
On December 4, 2020, Novo Nordisk submitted to the FDA a marketing application for weight loss with Smeiglutide 2.4mg subcutaneously injected once a week.
In April 2021, it was approved by the State Food and Drug Administration (NMPA) for the treatment of adult type 2 diabetes mellitus and reducing the risk of cardiovascular adverse events in patients with T2DM combined with cardiovascular disease.
On December 3, 2021, it was included in the "National Basic Medical Insurance, industrial injury Insurance and maternity Insurance Drug Catalog (2021)".
character
This product is colorless or almost colorless clear isotonic liquid; pH=7.4.
Fold edit this paragraph for indications
This product is suitable for glycemic control in adults with type 2 diabetes: adults with type 2 diabetes who are treated with metformin and/or sulfonylurea on the basis of diet control and exercise and still have poor glycemic control.
It is indicated to reduce the risk of major cardiovascular adverse events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus with cardiovascular disease.
Fold and edit this section specification
The specifications of this product are:
1.34mg/ml, 1.5ml (Pre-filled Injection pen)
1.34mg/ml, 3ml (Pre-filled Injection pen)
Products you are interested in
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}